Needham Reiterates Buy on Cara Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Cara Therapeutics (NASDAQ:CARA) and maintained a $5 price target.

March 28, 2024 | 9:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer reiterates a Buy rating on Cara Therapeutics with a $5 price target.
The reiteration of a Buy rating by a reputable analyst like Joseph Stringer, along with maintaining a $5 price target, suggests a positive outlook on CARA's stock. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100